UBQLN4: A Potential Drug Target for Various Diseases (G56893)

Target Name: UBQLN4

NCBI ID: G56893

UBQLN4

UBQLN4: A Potential Drug Target for Various Diseases

UBQLN4 (C1orf6) is a protein that is expressed in various tissues throughout the body. It is a member of the BCL-2 gene family, which is known for its role in regulating cell growth and survival. UBQLN4 has been shown to play a role in the development and progression of various diseases, including cancer. As a result, it has potential as a drug target or biomarker.

UBQLN4 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is highly conserved, with a calculated pI of 4.78 and a predicted monomeric molecular weight of 35 kDa. UBQLN4 is a member of the BCL-2 gene family, which is known for its role in regulating cell growth and survival. The BCL-2 gene family includes several proteins, including BCL-2, BCL-3, and BCL-4, which are involved in the regulation of apoptosis, cell cycle progression, and other cellular processes.

UBQLN4 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that UBQLN4 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. Overexpression of UBQLN4 has been shown to promote the growth and survival of cancer cells, as well as the development of new tumors.

In addition to its role in cancer, UBQLN4 has also been shown to play a role in the development of other diseases. For example, studies have shown that UBQLN4 is overexpressed in various types of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Overexpression of UBQLN4 has been shown to promote the development and progression of neurodegenerative diseases.

UBQLN4 has also been shown to play a role in the development of diseases that are characterized by inflammation and autoimmune responses. For example, studies have shown that UBQLN4 is overexpressed in various types of inflammatory diseases, including rheumatoid arthritis and multiple sclerosis. Overexpression of UBQLN4 has been shown to promote the development and progression of inflammatory diseases.

In addition to its role in disease, UBQLN4 has also been shown to be a potential drug target. Studies have shown that UBQLN4 can be targeted by small molecules and antibodies, and that it is a good candidate for drug development. For example, studies have shown that UBQLN4 can be inhibited by the small molecule inhibitor, UBQ-1, which has been shown to be a potential drug for the treatment of various diseases, including cancer and neurodegenerative diseases.

In conclusion, UBQLN4 is a protein that is expressed in various tissues throughout the body and has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and inflammatory diseases. As a result, UBQLN4 has potential as a drug target or biomarker. Further research is needed to fully understand the role of UBQLN4 in disease and to develop effective treatments.

Protein Name: Ubiquilin 4

Functions: Regulator of protein degradation that mediates the proteasomal targeting of misfolded, mislocalized or accumulated proteins (PubMed:15280365, PubMed:27113755, PubMed:29666234, PubMed:30612738). Acts by binding polyubiquitin chains of target proteins via its UBA domain and by interacting with subunits of the proteasome via its ubiquitin-like domain (PubMed:15280365, PubMed:27113755, PubMed:30612738). Key regulator of DNA repair that represses homologous recombination repair: in response to DNA damage, recruited to sites of DNA damage following phosphorylation by ATM and acts by binding and removing ubiquitinated MRE11 from damaged chromatin, leading to MRE11 degradation by the proteasome (PubMed:30612738). MRE11 degradation prevents homologous recombination repair, redirecting double-strand break repair toward non-homologous end joining (NHEJ) (PubMed:30612738). Specifically recognizes and binds mislocalized transmembrane-containing proteins and targets them to proteasomal degradation (PubMed:27113755). Collaborates with DESI1/POST in the export of ubiquitinated proteins from the nucleus to the cytoplasm (PubMed:29666234). Also plays a role in the regulation of the proteasomal degradation of non-ubiquitinated GJA1 (By similarity). Acts as an adapter protein that recruits UBQLN1 to the autophagy machinery (PubMed:23459205). Mediates the association of UBQLN1 with autophagosomes and the autophagy-related protein LC3 (MAP1LC3A/B/C) and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:23459205)

The "UBQLN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBQLN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets